2-vinylheptanoic acid | 4436-85-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-vinylheptanoic acid
• 英文别名: 2-pentyl-but-3-enoic acid；2-Pentyl-but-3-ensaeure；2-Amyl 3-butenoic acid；2-ethenylheptanoic acid
• CAS: 4436-85-5
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: VJICCZIMJKBXME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-vinylheptanoic acid 、 2-萘胺 生成 2-pentyl-but-3-enoic acid-[2]naphthylamide
  参考文献：
  名称：

  Polymerization. XII. The Metalation of Olefins and Dienes and their Use in Alfin Polymerization of Butadiene¹

  摘要：

  DOI：

  10.1021/ja01164a125
• 作为产物：
  描述：

  反式-2-辛烯-1-醇 在 乙二醇二甲醚溴化镍 、 2,2':6',2'':6'',2'''-四联吡啶 、 sodium carbonate 、 三乙胺 、 锌 作用下， 以 二氯甲烷 为溶剂， 40.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 生成 2-vinylheptanoic acid
  参考文献：
  名称：

  Ligand-Controlled Regiodivergent Ni-Catalyzed Reductive Carboxylation of Allyl Esters with CO₂

  摘要：

  A novel Ni-catalyzed regiodivergent reductive carboxylation of allyl esters with CO2 has been developed. This mild, user-friendly, and operationally simple method is characterized by an exquisite selectivity profile that is dictated by the ligand backbone.

  DOI：

  10.1021/ja509077a

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• Switchable Site-Selective Catalytic Carboxylation of Allylic Alcohols with CO₂
  作者：Manuel van Gemmeren、Marino Börjesson、Andreu Tortajada、Shang-Zheng Sun、Keisho Okura、Ruben Martin

  DOI：10.1002/anie.201702857

  日期：2017.6.1

  allylic alcohols has been developed in which CO2 is used with dual roles, both facilitating C-OH cleavage and as a C1 source. This protocol is characterized by its mild reaction conditions, absence of stoichiometric amounts of organometallic reagents, broad scope, and exquisite regiodivergency which can be modulated by the type of ligand employed.

  已经开发了烯丙醇的可切换的位点选择性催化羧化，其中CO 2具有双重作用，既促进C-OH裂解，又作为C 1来源。该方案的特点是反应条件温和，不存在化学计量数量的有机金属试剂，范围广，可以通过所用配体的类型调节的极好的区域差异。
• ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS
  申请人：OSRAM OLED GmbH

  公开号：US20180277778A1

  公开（公告）日：2018-09-27

  The invention relates to an organic electronic component ( 100 ) comprising at least one charge generation layer ( 5 ) which has an organically p-doped region ( 5 a ) that contains a zinc complex as a p-dopant, said zinc complex in turn containing at least one ligand L of the following structure: formula (I) wherein R1 and R2 can be oxygen, sulphur, selenium, NH or NR4 independently from one another, wherein R4 is selected from the group containing alkyl or aryl and which can be bonded to R3; and wherein R3 is selected from the group containing alkyl, long-chain alkyl, cycloalkyl, halogen alkyl, at least partially halogenated long-chain alkyl, halogen cycloalkyl, aryl, arylene, halogen aryl, heteroaryl, heteroarylene, heterocyclic alkylene, heterocycloalkyl, halogen heteroaryl, alkenyl, halogen alkenyl, alkynyl, halogen alkynyl, ketoaryl, halogen ketoaryl, ketoheteroaryl, ketoalkyl, halogen ketoalkyl, ketoalkenyl, halogen ketoalkenyl, halogen alkyl aryl, and halogen alkyl heteroaryl, wherein, for suitable groups, one or a number of non-adjacent CH2 groups can be replaced by —O—, —S—, —NH—, —NR ∘∘∘ —, —SiR ∘ R ∘∘ —, —CO—, —COO—, —COR ∘ OR ∘∘ —, —OCO—, —OCO—O—, —SO2-, —S—CO—, —CO—S—, —O—CS—, —CS—O—, —CY1=CY2 or —C≡C— independently from one another, and in such a way that O and/or S atoms are not directly bonded to one another, and are replaced optionally with aryl- or heteroaryl preferably containing between 1 and 30 C atoms (terminal CH3 groups are understood to be CH2 groups in the sense of CH2-H). The invention further relates to the use of a zinc complex as a p-dopant in charge generation layers.

  本发明涉及一种有机电子元件（100），包括至少一个具有有机p-掺杂区域（5a）的电荷生成层（5），该区域含有锌络合物作为p-掺杂剂，所述锌络合物又包含至少一个具有以下结构的配体L：式（I），其中R1和R2可以分别独立地为氧、硫、硒、NH或NR4，其中R4选自含有烷基或芳基的基团，可以与R3结合；R3选自含有烷基、长链烷基、环烷基、卤代烷基、至少部分卤代长链烷基、卤代环烷基、芳基、芳烯基、卤代芳基、杂环芳基、杂环芳烯基、杂环烷基、卤代杂环芳基、烯基、卤代烯基、炔基、卤代炔基、酮基芳基、卤代酮基芳基、酮基杂环芳基、酮基烷基、卤代酮基烷基、酮基烯基、卤代酮基烯基、卤代烷基芳基和卤代烷基杂环芳基的基团，对于适当的基团，一个或多个非相邻的CH2基团可以被—O—、—S—、—NH—、—NR∘∘∘—、—SiR∘R∘∘—、—CO—、—COO—、—COR∘OR∘∘—、—OCO—、—OCO—O—、—SO2-、—S—CO—、—CO—S—、—O—CS—、—CS—O—、—CY1=CY2或—C≡C—中的一个或多个代替，且使O和/或S原子不直接结合，可选地用含有1至30个C原子的芳基或杂环芳基替换（末端CH3基团在CH2-H的意义上被理解为CH2基团）。该发明还涉及在电荷生成层中使用锌络合物作为p-掺杂剂。
• [EN] ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS<br/>[FR] SELS D’ACIDE ARYLALKYLCARBOXYLIQUE, PROCÉDÉ POUR LEUR PRÉPARATION ET FORMES GALÉNIQUES
  申请人：SHASUN CHEMICALS AND DRUGS LTD

  公开号：WO2011001228A1

  公开（公告）日：2011-01-06

  The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention arc prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients.

  该发明特别公开了一种制备芳基烷基羧酸盐的过程，包括制备水溶性碱溶液，在4℃至121℃的温度范围内将芳基烷基羧酸添加到碱溶液中，通过加热和/或搅拌使其变为清澈的溶液，然后浓缩和冷却以获得芳基烷基羧酸盐。因此，该发明公开了不含有机溶剂/酸的芳基烷基羧酸盐的固体口服剂型和组合物。该发明的芳基烷基羧酸盐的固体口服剂型是通过原位制备芳基烷基羧酸和碱来获得晶体/粉末形式的芳酸烷基羧酸盐，可以使用药用辅料来制备。
• ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS
  申请人：Chodankar Nandkumar

  公开号：US20110144207A1

  公开（公告）日：2011-06-16

  The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C. for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention are prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients.

  本发明特别公开了一种制备芳基烷基羧酸盐的方法，包括制备水溶性碱性溶液，将芳基烷基羧酸加入该碱性溶液中，在4℃至121℃的温度范围内获得清晰的溶液，最好通过加热和/或搅拌、浓缩和冷却来获得芳基烷基羧酸盐。因此，本发明公开了不含有机溶剂/酮的芳基烷基羧酸盐的固体口服剂型和组合物。本发明的芳基烷基羧酸盐的固体口服剂型组合物通过从芳基烷基羧酸和碱基中原位制备获得，以获得晶体/粉末形式的芳酸烷基羧酸盐，可以使用药用辅料，也可以不使用。